Jin Medical International Ltd. Implements Strategic Share Consolidation to Enhance Nasdaq Compliance

Jin Medical's Strategic Move for Nasdaq Compliance

Jin Medical International Ltd., a prominent name in the rehabilitation medical equipment sector, has recently taken a significant step towards strengthening its market position. On March 11, 2026, the company declared its approval of a 1-for-20 share combination as part of a broader strategy to satisfy the ongoing compliance demands of Nasdaq. This decisive action, authorized during an extraordinary general meeting on January 30, 2026, is expected to reshape the company’s capital structure and enhance its financial health.

Background on Jin Medical International Ltd.

Founded in 2006 and headquartered in Changzhou, Jiangsu Province of China, Jin Medical is dedicated to designing, developing, manufacturing, and marketing a range of products aimed at improving the quality of life for people with disabilities and the elderly. With over 230,000 square feet of manufacturing space across two plants and plans for a larger facility in Anhui Province, the company's infrastructure supports an enduring commitment to innovation and quality. Jin Medical’s product portfolio includes more than 30 models of wheelchairs, which are popular among distributors in both Japan and China.

Details of the Stock Combination

The stock combination will officially take effect on March 16, 2026, at 9:00 AM ET. With this consolidation, the company's existing shares will be restructured, with every 20 shares combining into a single share. This means that the previously outstanding 136,547,100 Class A shares will reduce to approximately 6,827,355, while Class B shares will decrease from 20,000,000 to 1,000,000.

The company's authorized share capital will undergo a transformation, reclassified into two classes: Class A and Class B ordinary shares, divided into $50,000—45 million for Class A and 5 million for Class B, both at a par value of $0.001 each. This strategy is designed to align the company better with Nasdaq's stringent listing criteria.

Purpose Behind the Consolidation

The rationale behind this proactive measure is multifaceted. Firstly, the company aims to sustain compliance with Nasdaq’s requirements enabling it to retain its listing status. Furthermore, consolidating shares is an essential step towards stabilizing Jin Medical's long-term capital structure.